BioArctic Q1: Building value and diversifying
Redeye's positive view on BioArctic was strengthened after today's Q1 report. The company continues to build value in the portfolio and diversify, thus reducing risk. We are confident in BioArctic's long-term capability to innovate and create value for all stakeholders.